14:30 - 15:00 Opening ceremony

Chairs: J Gribben (EHA), M Qari (PAHA) & A El-Beshlawy (ESHR)

15:00 - 16:30 SCIENTIFIC SESSION

Laboratory hematology

Chair: A Kamel (ESHR)

• Laboratory management overview 2018
  MC Béné (France)
• High throughput flow cytometry for combined MRD measurements and immune monitoring
  A Orfao (Spain)
• Next generation sequencing (NGS) for MRD detection in acute lymphoblastic leukemia
  J Trka (Czech Republic)

16:30 - 17:00 ABSTRACT PITCH SESSION 1

Chair: JB Hansen (Norway)

• 1.1 THE BLEEDING FAMILY
  Y El Chazli (Alexandria University Children's Hospital, Egypt)
• 1.2. A SIMPLIFIED HEALTH EDUCATION PROGRAM IMPROVES KNOWLEDGE AND PRACTICES OF HOME TREATMENT IN HEMOPHILIA A ADOLESCENTS IN A DEVELOPING COUNTRY: INTERVENTIONAL STUDY
  M Hesham (Zagazig University, Egypt)
• 1.3. IMPLICATION OF HMOX1 AND CCR5 GENOTYPES ON CLINICAL PHENOTYPE OF EGYPTIAN PATIENTS WITH SICKLE CELL ANEMIA
  S Bakr (Faculty of Medicine, Fayoum University, Egypt)
• 1.4. SURFACTANT PROTEIN D AS A MARKER FOR PULMONARY COMPLICATIONS IN PEDIATRIC PATIENTS WITH SICKLE CELLDISEASE: RELATION TO LUNG FUNCTION TESTS
  AAT Tantawy (Faculty of Medicine Ain Shams University, Cairo, Egypt)
• 1.5. VWF LEVEL AND THR789ALA GENETIC VARIANTS ARE ASSOCIATED WITH THE RISK OF SEVER PREECLAMPSIA
  NF Osman (Menoufia University, Egypt)
• 1.6. MONITORING THE QUALITY INDICATORS FOR BLOOD TRANSFUSION SERVICES IS A METHOD FOR IMPROVEMENT AT KING ABDULAZIZ UNIVERSITY HOSPITAL
  T Elgemmezi (Blood Transfusion Services - Kauh - Jeddah, Saudi Arabia)
• 1.7. IMPACT OF STORAGE, LEUCOFILTRATION, ASCORBIC ACID FORTIFICATION ON RED CELL-DERIVED MICROPARTICLES IN STORED PACKED RBCS. A FLOW CYTOMETRY AND PROCOAGULANT STUDY.
  RF Raghda Fouda (Cairo University, Kasr Alainy, Egypt)

17:00 - 17:30 Coffee break

17:30 - 18:30 BMS SATELLITE SYMPOSIUM

New horizons in cancer immunotherapy, Management of cHL

• New horizons in cancer immunotherapy, Management of cHL
  H AbdelAzim (Egypt)

18:30 - 19:30 Welcome reception & Poster session

09:30 - 10:30 SCIENTIFIC SESSION

Acute & Chronic Leukemia

Chair: H Özsan (TSH)

• CLL overview 2018
  G Gaidano (Italy)
• Toxicity in hematologic malignancies: Considerations in bone marrow transplant, survivors and real world hematology patients
  J Gribben (United Kingdom)
• Standard therapy intensive or non intensive
  O Ottmann (United Kingdom)

10:30 - 11:30 SCIENTIFIC SESSION

Hemoglobinopathies

Chair: A El-Beshlawy (ESHR)

• Targeting iron hemostasis for the improvement of ineffective erythropoiesis in beta-thalassemia
  A Nai (Italy)
• Clinical trials in hemoglobinopathies
  M Abboud (Lebanon)

11:30 - 13:30 Prayer, lunch & poster viewing

12:30 - 13:30 BMS SATELLITE SYMPOSIUM

Treatment advances in hematological malignancies

• Efficacy and safety of TKIs in the treatment of chronic myeloid leukemia
  A AlGhandour (Egypt)
• Immuno-Oncology: An emerging modality in Hodgkin Lymphoma treatment
  A AlGhandour (Egypt)

13:30 - 15:00 JOINT SYMPOSIUM

Regional perspectives on hemoglobinopathies

Chair: M Qari (PAHA)

• Introduction EHA Topics-in-Focus "Hemoglobinopathies"
  J Gribben (EHA)
  
  
• Bahrain experience in diagnosing and preventive measures to reduce the prevalence of hemoglobinopathies 
  A Radhi (Bahrain)
• Screening for iron deficiency and hemoglobinopathy prevalence in Saudi Arabia
  T Owaidah (Saudi Arabia)
• Iron overload and chelation in hemoglobinopathies
  Ş Unal (Turkey)
• Deferasirox in comparison with Desferrioxamine in Thalassemia Major Patients
  H Al-Momen (Iraq)
• Advances in the management of thalassemia
  A El-Beshlawy (Egypt)
• Novel therapies in Sickle Cell Disease (SCD)
  S Alkindi (Oman)

15:00 - 16:00 SCIENTIFIC SESSION

Lymphoma

Chair: S Al Jaouni (SSH)

• PTCL: Evidence for subtype specific treatment approaches?
  F D'Amore (Denmark)
• From epidemiology to treatment decisions (the role of T cell registries)
  M Federico (Italy)

16:00 - 16:30 Coffee break

16:30 - 18:00 SCIENTIFIC SESSION

Red cells & iron

Chair: A Ibrahim (LSHBT)

• Anemia in the elderly
  D Girelli (Italy)
• Control of erythropoiesis
  J Davies (United Kingdom)
• New modes of hepcidin regulation
  H Drakesmith (United Kingdom)

18:00 - 18:45 ABSTRACT PITCH SESSION 2

Chair: J Gribben (United Kingdom)

• 2.1. IMPACT OF HEPATITIS C VIRUS ON TREATMENT-RELATED HEPATIC TOXICITY AND OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS
  SA Ahmed (Internal Medicine Department, Qena University Hospital, Qena, Egypt)
• 2.2. CHARACTERISTICS OF SPLENIC MARGINAL ZONE LYMPHOMA: CLINICAL, HEMATOLOGIC, AND FLOW CYTOMETRY FINDINGS OF 34 CASES
  MA Al-Mashta (Department of Haematopathology, Iraq)
• 2.3. VASCULAR ENDOTHELIAL GROWTH FACTOR & BASIC FIBROBLAST GROWTH FACTOR POLYMORPHISM AS PROGNOSTIC FACTORS IN NON-HODGKIN LYMPHOMA
  E NasrEldin (Assiut University - Faculty of Medicine - Clinical Pathology Department, Egypt)
• 2.4. PROGNOSTIC IMPACT OF MULTIPLE MYELOMA CYTOGENETIC ABNORMALITIES ON OUTCOME OF AUTOLOGOUS BONE MARROW TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
  MD Denewer (Oncology Center of Mansoura University, Egypt)
• 2.5. CLINIC-PATHOLOGICAL FEATURES OF MULTIPLE MYELOMA AND IMPACT OF HEPATITIS C INFECTION.
  S El-Ashwah (Mansoura University, Mansoura, Egypt)
• 2.6. CLINICAL IMPACT OF NATURAL KILLER CELLS AND NATURAL KILLER LIKE T-CELL POPULATION PERCENTAGE IN ACUTE MYELOID LEUKEMIA
  EJ Jamal (Internal Medicine Department - Faculty of Medicine - Mansoura University, Egypt)
• 2.7. BCR-ABL1/ABL REDUCTION RATIO AND ITS SUPERIORITY AS A PREDICTOR FOR OUTCOME IN EGYPTIAN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
  ME Elbogdady (Oncology Center Mansoura University, Egypt)
• 2.8. EFFECT OF ABCG2, SLCO1B3 GENE POLYMORPHISM ON RESPONSE OF IMATINIB MESYLATE IN CML PATIENTS
  MM Omran (National Cancer Institute - Cairo University, Egypt)
• 2.9. LIPOCALIN 2: A KEY DRIVER OF THE PATHOLOGICAL EVOLUTION OF MYELODYSPLASTIC SYNDROME
  DD Salem (Faculty of Medicine, Ain Shams University, Egypt)
• 2.10. THE PREVALENCE OF CALR MUTATIONS TYPE 1 AND TYPE 2 IN SUDANESE PATIENTS WITH JAK2 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
  I Osman (Al Neelain University, Sudan)
• 2.11. CALR MUTATIONS IN EGYPTIAN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
  LMS Saleh (Hematology Section, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt)

09:30 - 10:15 SCIENTIFIC SESSION

Multiple myeloma

Chair: WF Al Tameemi (ISOH)

• Key note lecture: Myeloma overview 2018
  P Sonneveld (The Netherlands)

10:15 - 11:00 ABSTRACT PITCH SESSION 3

Chair: O Ottmann (United Kingdom)

• 3.1. GENETIC POLYMORPHISMS IN CANDIDATE GENES INCLUDING CEP72 ARE NOT ASSOCIATED WITH INCREASED VINCRISTINERELATED PERIPHERAL NEUROPATHY IN ARAB CHILDREN TREATED FOR ACUTE CHILDHOOD LEUKEMIA: A SINGLE INSTITUTION STUDY
  HG El-Khoury (American University of Beirut, Lebanon)
• 3.2. HOW HCV INFECTION AFFECT CLL PATIENTS?
  SH El Ashwah (Mansoura University, Mansoura, Egypt)
• 3.3. THE DIAGNOSTIC AND PROGNOSTIC VALUE OF CD38 AND CD49D EXPRESSIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
  SF Gohar (Faculty of Medicine, Menoufia University, Egypt)

11:00 - 11:30 Coffee break

11:30 - 12:30 SCIENTIFIC SESSION

Thrombosis & hemostasis

Chair to be announced

• Future challenges in prevention and treatment of venous thrombosis
  JB Hansen (Norway)
• Genetic risk factors of venous thrombosis
  P Morange (France)

12:30 - 13:00 Closing ceremony

Chair: P Sonneveld (EHA), M Qari (PAHA) & A Kamel (ESHR)

13:00 - 14:00 Farewell lunch